Fig. 5: Silencing of LSD1 and PRMT6 together suppresses polyQ-expanded AR neurotoxicity. | Nature Communications

Fig. 5: Silencing of LSD1 and PRMT6 together suppresses polyQ-expanded AR neurotoxicity.

From: LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates spinobulbar muscular atrophy phenotypes in flies and mice

Fig. 5

a Analysis of the eye phenotype in flies expressing EGFP, AR0Q, or AR52Q with or without RNAi to silence dLsd1 and the PRMT6 fly ortholog Dart8. Shown are representative images from 10–15 flies/genotype. b RT-PCR analysis of dLsd1 mRNA transcript levels normalized to tubulin (n = 3 flies/genotype). c Disease severity in AR52Q flies with or without dLsd1 and Dart8 silencing (n = 15 AR52Q; n = 16 AR52Q dLsd1 RNAi and AR52Q Dart8 RNAi; n = 12 AR52Q dLsd1 RNAi/Dart8 RNAi). Graphs show mean ± SEM; two-tailed Student t-test (b) or one-way ANOVA followed by Tukey HSD test (c). Source data are provided as a Source data file.

Back to article page